AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Avita Therapeutics

2.820

+0.0200.71%

Volume:91.70K

Turnover:257.83K

Market Cap:372.73M

PE:-0.09

High:2.850

Open:2.780

Low:2.780

Close:2.800

Loading ...

Overview Company News Filings

Stock Track | Avita Therapeutics Soars 11.20% on Breakthrough Clinical Data Presentation at ABA 2025

AVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025

Avita Medical's Cohealyx Wound Treatment Makes Commercial Launch in US; Shares Down 4%

MT Newswires Live

Guess which ASX All Ords stock just leapt 9% on big US news

AVITA Secures Manufacturing, Amends Distribution Agreement with US-Based Healthcare Tech Provider; Shares Rise 7%

MT Newswires Live

Does Avita Medical (RCEL) Have the Potential to Rally 73.72% as Wall Street Analysts Expect?

AVITA Medical Full Year 2024 Earnings: Misses Expectations

Simply Wall St.

AVITA Medical to Host Investor Webinar Briefing

Avita Medical Reports Wider Q4 Loss Despite Higher Revenue; Shares Up 12%

MT Newswires Live

AVITA Medical, Inc. (RCEL): A Bull Case Theory

Why AVITA Medical, Lovisa, Star, and Westgold shares are sinking today

Australian Shares Rise as November Inflation Data Signals Easing Potential; Avita Medical Lowers Revenue Guidance

MT Newswires Live

BUZZ-Australia-listed shares of AVITA Medical slump on forecast cut

AVITA Medical's shares sink 19% after another forecast cut

ASX Market Update: Inflation higher than expected as miners bounce back | January 8, 2025

The Market Herald

Why AVITA Medical, Block, Computershare, and GQG Partners shares are falling today

Avita Medical Lowers Q4, 2024 Revenue Guidance; Provides 2025 Forecast; Shares Slump 20%

MT Newswires Live

Why did this ASX All Ords stock just crash 17%?

Exploring High Growth Tech Stocks in the United States December 2024

Simply Wall St.

Why AVITA Medical, Life360, Newmont, and St Barbara shares are falling today

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/AVH.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AVH.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVH.AU\",,,,,undefined,":{"symbol":"AVH.AU","market":"AU","secType":"STK","nameCN":"Avita Therapeutics","latestPrice":2.82,"timestamp":1744870320000,"preClose":2.8,"halted":0,"volume":91704,"delay":0,"nameEN":"Avita Therapeutics","floatShares":3240540,"shares":132173290,"eps":-29.79001192210889,"marketStatus":"Not Yet Opened","change":0.02,"latestTime":"04-17 16:12:00 AEST","open":2.78,"high":2.85,"low":2.78,"amount":257831,"amplitude":0.025,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-29.79001192210889,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":0,"adr":0,"adrRate":8,"exchange":"ASX","adjPreClose":2.8,"openAndCloseTimeList":[[1744848000000,1744869600000]],"volumeRatio":0.5482190534094435,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVH.AU\",,,,,undefined,":{"symbol":"AVH.AU","floatShares":3240540,"roa":"-36.97%","roe":"-230.96%","lyrEps":-29.790012,"volumeRatio":0.5482190534094435,"shares":132173290,"dividePrice":0,"high":2.85,"amplitude":0.025,"preClose":2.8,"low":2.78,"week52Low":2.34,"pbRate":"53.16","psRate":"3.72","week52High":4.52,"institutionHeld":0,"latestPrice":2.82,"eps":-29.79001192210889,"divideRate":0,"volume":91704,"delay":0,"ttmEps":-29.79001192210889,"open":2.78,"prevYearClose":4.25,"prevWeekClose":2.82,"prevMonthClose":2.72,"prevQuarterClose":2.72,"fiveDayClose":2.8,"twentyDayClose":3.02,"sixtyDayClose":2.76},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AVH.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1141929202","title":"Stock Track | Avita Therapeutics Soars 11.20% on Breakthrough Clinical Data Presentation at ABA 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1141929202","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141929202?lang=en_us&edition=fundamental","pubTime":"2025-04-10 08:02","pubTimestamp":1744243368,"startTime":"0","endTime":"0","summary":"Avita Therapeutics  shares are soaring 11.20% in Thursday's trading session, following the announcement of the company's plans to present groundbreaking clinical data at the American Burn Association  2025 Annual Meeting. The significant uptick in share price reflects investors' positive reaction to the company's expanding evidence base and commitment to advancing burn and wound care treatments.Investors appear particularly encouraged by the breadth and depth of the data being presented. Key hig","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Avita Therapeutics Soars 11.20% on Breakthrough Clinical Data Presentation at ABA 2025","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AVH.AU"],"gpt_icon":0},{"id":"2526433613","title":"AVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2526433613","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526433613?lang=en_us&edition=fundamental","pubTime":"2025-04-10 04:05","pubTimestamp":1744229100,"startTime":"0","endTime":"0","summary":"Sixteen abstracts to present real-world findings and clinical innovations across AVITA Medical’s expanded portfolio, including RECELL, Cohealyx, and PermeaDerm. VALENCIA, Calif., April 09, 2025  -- AVITA Medical, Inc. , a leading therapeutic acute wound care company delivering a portfolio of transformative solutions, today announced 16 abstracts to be presented at the American Burn Association  2025 Annual Meeting, taking place April 8-11 in Phoenix, Arizona. The presentations will feature real-world and clinical data on AVITA Medical’s wound care portfolio, including RECELL, Cohealyx, and PermeaDerm, showcasing the company’s expanded evidence base and commitment to improving outcomes in burn and wound management. Visit AVITA Medical at booth #513 to learn more.Each year, more than 450,000 Americans require medical treatment for burn injuries, often facing prolonged hospitalization, multiple procedures, and complex wound management. AVITA Medical’s technologies are designed to address ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/avita-medical-present-breakthrough-clinical-200500697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["ABA.AU","BK7508","BK7067","BK7123","BK7139","BK4139","RCEL","AVH.AU"],"gpt_icon":0},{"id":"2524487472","title":"Avita Medical's Cohealyx Wound Treatment Makes Commercial Launch in US; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2524487472","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524487472?lang=en_us&edition=fundamental","pubTime":"2025-04-04 07:36","pubTimestamp":1743723362,"startTime":"0","endTime":"0","summary":"Avita Medical  launched wound care treatment Cohealyx in the US, according to a Friday filing with the Australian bourse.Cohealyx is a collagen-based dermal matrix branded by Avita Medical and co-developed with Regenity Biosciences, the filing stated. It is designed to provide wound bed through cellular migration and revascularization for faster closure.Avita Medical is enrolling participants in the Cohealyx I post-market trial.The company's shares were down almost 4% in recent Friday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AVH.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2520516026","title":"Guess which ASX All Ords stock just leapt 9% on big US news","url":"https://stock-news.laohu8.com/highlight/detail?id=2520516026","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520516026?lang=en_us&edition=fundamental","pubTime":"2025-03-18 08:51","pubTimestamp":1742259083,"startTime":"0","endTime":"0","summary":"Commenting on the new agreements helping to lift the ASX All Ords stock today, Avita Medical CEO Jim Corbett said:  These strategic agreements reflect our shared commitment to driving innovation and expanding market access, while ensuring that patients continue to receive first-in-class care. We look forward to leveraging our expertise to continue to drive innovation and growth in therapeutic acute wound care.  Lin Sun, chairman of Stedical Scientific, added:  PermeaDerm has demonstrated great healing results when used for various wounds. We are excited to expand our collaboration with Avita Medical through this manufacturing agreement. This partnership ensures a robust supply chain for PermeaDerm and strengthens our commitment to delivering cutting-edge solutions to the global market.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/18/guess-which-asx-all-ords-stock-just-leapt-9-on-big-us-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["XAO.AU","AVH.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2520633277","title":"AVITA Secures Manufacturing, Amends Distribution Agreement with US-Based Healthcare Tech Provider; Shares Rise 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2520633277","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520633277?lang=en_us&edition=fundamental","pubTime":"2025-03-18 07:49","pubTimestamp":1742255396,"startTime":"0","endTime":"0","summary":"AVITA Medical  secured a new contract manufacturing agreement and amended its existing distribution agreement for its biosynthetic wound matrix product PermeaDerm, for the treatment of wounds, with Stedical Scientific, according to a Tuesday filing with the Australian bourse.Under the manufacturing agreement, effective Monday, the company will produce PermeaDerm at its Ventura, California facility, while the amended distribution deal revises revenue-sharing terms with Stedical, the filing said.AVITA will retain 60% of sales, with Stedical receiving 40% after manufacturing costs. The agreement also sets performance milestones and extends the contract term, the filing added.Shares of the company rose 7% in recent Tuesday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","HCSG","BK7067","BK4137","AVH.AU"],"gpt_icon":0},{"id":"2519856944","title":"Does Avita Medical (RCEL) Have the Potential to Rally 73.72% as Wall Street Analysts Expect?","url":"https://stock-news.laohu8.com/highlight/detail?id=2519856944","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519856944?lang=en_us&edition=fundamental","pubTime":"2025-03-13 21:55","pubTimestamp":1741874105,"startTime":"0","endTime":"0","summary":"Shares of Avita Medical Inc.  have gained 4.3% over the past four weeks to close the last trading session at $8.98, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $15.60 indicates a potential upside of 73.7%.The average comprises five short-term price targets ranging from a low of $11 to a high of $21, with a standard deviation of $3.71. While the lowest estimate indicates an increase of 22.5% from the current price level, the most optimistic estimate points to a 133.9% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/does-avita-medical-rcel-potential-135505486.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["RCEL","BK7508","AVH.AU","BK7067","BK4139"],"gpt_icon":0},{"id":"2511672246","title":"AVITA Medical Full Year 2024 Earnings: Misses Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2511672246","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511672246?lang=en_us&edition=fundamental","pubTime":"2025-02-15 22:16","pubTimestamp":1739628972,"startTime":"0","endTime":"0","summary":"NasdaqCM:RCEL Earnings and Revenue Growth February 15th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue missed analyst estimates by 2.2%. Earnings per share  also missed analyst estimates by 4.1%.Looking ahead, revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.The company's shares are up 22% from a week ago.It's still necessary to consider the ever-present spectre of investment risk.   We've identified 1 warning sign  with AVITA Medical, and understanding it should be part of your investment process.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/avita-medical-full-2024-earnings-141612158.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AVH.AU","RCEL"],"gpt_icon":0},{"id":"2511695448","title":"AVITA Medical to Host Investor Webinar Briefing","url":"https://stock-news.laohu8.com/highlight/detail?id=2511695448","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511695448?lang=en_us&edition=fundamental","pubTime":"2025-02-14 22:15","pubTimestamp":1739542500,"startTime":"0","endTime":"0","summary":"VALENCIA, Calif., Feb. 14, 2025  -- AVITA Medical, Inc. , a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O’Toole, Chief Financial Officer, on February 18, 2025, at 2:00 p.m. Pacific Standard Time .About AVITA Medical, Inc.AVITA Medical is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering a groundbreaking solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/avita-medical-host-investor-webinar-141500288.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RCEL","BK4218","BK4181","HST","AVH.AU","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"2511682256","title":"Avita Medical Reports Wider Q4 Loss Despite Higher Revenue; Shares Up 12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511682256","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511682256?lang=en_us&edition=fundamental","pubTime":"2025-02-14 11:40","pubTimestamp":1739504457,"startTime":"0","endTime":"0","summary":"Avita Medical  reported Friday a loss of $0.44 per diluted share in the fourth quarter of 2024, compared with a loss of $0.28 per diluted share in the same period in 2023.Analysts polled by Visible Alpha also expected a loss of $0.44.The dual-listed firm said the wider net loss was due to higher operating expenses and lower other income, net, partially offset by higher gross profit.Total revenue in the quarter ended Dec. 31, 2024, came in at $18.4 million, compared with $14.2 million in the corresponding period in the prior year. Analysts polled by Visible Alpha expected $20.3 million.The company said it expects its full-year 2025 commercial revenue to be in the range of $100 to $106 million, reflecting growth of approximately 55% to 65% over the full-year 2024.The company's shares surged past 12% in recent Friday trade in Australia.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AVH.AU"],"gpt_icon":0},{"id":"2502026876","title":"AVITA Medical, Inc. (RCEL): A Bull Case Theory","url":"https://stock-news.laohu8.com/highlight/detail?id=2502026876","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502026876?lang=en_us&edition=fundamental","pubTime":"2025-01-10 03:04","pubTimestamp":1736449496,"startTime":"0","endTime":"0","summary":"We came across abullish thesison AVITA Medical, Inc.  on Substack by Steve Wagner. In this article, we will summarize the bulls’ thesis on RCEL. AVITA Medical, Inc. 's share was trading at $8.94 as of Jan 8th.A doctor interacting with a patient, discussing the progress of their treatment.Avita Medical  has recently secured FDA approval for its new RECELL GO mini, a disposable cartridge designed specifically for treating smaller wounds up to 480 square centimeters. This innovative product fills a critical gap in the wound care market, particularly for high-volume, smaller wounds typically encountered in trauma and burn centers. Unlike the standard RECELL GO, which is capable of treating wounds up to 1,920 square centimeters, the mini version uses the same multi-use processing device but with an optimized cartridge for smaller skin samples. This adjustment leads to reduced resource consumption and waste, making the product more cost-effective, a key consideration for hospitals facing bud","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/avita-medical-inc-rcel-bull-190456504.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USJW.SI","TSYW.SI","PSQ","MNQmain","TQQQ","NQmain","RCEL","USAW.SI","SQQQ",".IXIC","QID","NVIW.SI","BK4139","QLD","AVH.AU"],"gpt_icon":1},{"id":"2502193031","title":"Why AVITA Medical, Lovisa, Star, and Westgold shares are sinking today","url":"https://stock-news.laohu8.com/highlight/detail?id=2502193031","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502193031?lang=en_us&edition=fundamental","pubTime":"2025-01-09 09:26","pubTimestamp":1736385990,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index(ASX: XJO) is out of form and dropping into the red on Thursday. In afternoon trade, the benchmark index is down 0.4% to 8,314.6 points. Four ASX shares that are falling more than ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/09/why-avita-medical-lovisa-star-and-westgold-shares-are-sinking-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7508","XJO.AU","BK7104","LOV.AU","BK7506","WGX.AU","BK7067","BK7078","BK7128","AVH.AU","SGR.AU"],"gpt_icon":0},{"id":"2501790040","title":"Australian Shares Rise as November Inflation Data Signals Easing Potential; Avita Medical Lowers Revenue Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2501790040","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501790040?lang=en_us&edition=fundamental","pubTime":"2025-01-08 14:22","pubTimestamp":1736317322,"startTime":"0","endTime":"0","summary":"Australian shares rose on Monday's close despite losses from Wall Street and other Asian markets as data from the country's inflation gauge signaled that policymakers may have to cut interest rates so","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","XJO.AU","CBA.AU","GQG.AU","XAO.AU","AVH.AU"],"gpt_icon":0},{"id":"2501804799","title":"BUZZ-Australia-listed shares of AVITA Medical slump on forecast cut","url":"https://stock-news.laohu8.com/highlight/detail?id=2501804799","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501804799?lang=en_us&edition=fundamental","pubTime":"2025-01-08 12:34","pubTimestamp":1736310856,"startTime":"0","endTime":"0","summary":"* ASX-listed shares of AVITA Medical AVH.AX RCEL.O fall as much as 20.2% to A$3.470. ** Stock last down about 18.8%, set for deepest one-day decline since Oct 2023","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nL4N3O409O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVH.AU","BK7508","BK4139","RCEL","BK7067"],"gpt_icon":0},{"id":"2501760209","title":"AVITA Medical's shares sink 19% after another forecast cut","url":"https://stock-news.laohu8.com/highlight/detail?id=2501760209","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501760209?lang=en_us&edition=fundamental","pubTime":"2025-01-08 11:10","pubTimestamp":1736305807,"startTime":"0","endTime":"0","summary":"AVITA Medical's shares sink 19% after another forecast cutBy Nikita Maria JinoJan 8 (Reuters) - AVITA Medical's AVH.AX Australia-listed shares sank nearly 19% on Wednesday, set for their worst day in ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nL4N3O402C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RCEL","BK4139","BK7508","AVH.AU"],"gpt_icon":0},{"id":"2501988077","title":"ASX Market Update: Inflation higher than expected as miners bounce back | January 8, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2501988077","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501988077?lang=en_us&edition=fundamental","pubTime":"2025-01-08 10:28","pubTimestamp":1736303280,"startTime":"0","endTime":"0","summary":"The ASX200 has been up 0.65% at 8,338 points in afternoon trade.Inflation edged upmore than expected, from2.1% to 2.3%. More importantly, trimmed mean inflation  came in at3.2%,still outside the RBA’s 2% to 3% target range.While consensus had shifted towards a 70% probability of a rate cut in February, some analysts don’t see this happening until later in the year.Materials has bounced back and has been the biggest winner, up 1.5%, followed by Financials, up 0.85%, and Health Care, up 0.75%.IT has lost the most ground, down 0.7%, followed by Real Estate and Telecommunication, both down 0.3%.Meeka Metalshas been up 10.5% on a breakthrough in its drilling program at St Anne’s within the Murchison Gold Project. The latest assays reveal bonanza-grade gold intersections, bolstering plans for an expanded Stage 1 open pit.Orthocell  has been up 5.6% after posting a third consecutive quarter of record revenue. The company reported a 46% increase in revenue to $2.21 million for the December ’24","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-update-inflation-higher-than-expected-as-miners-bounce-back-january-8-2025-2025-01-08/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["MEK.AU","BK7104","BK7508","OCC.AU","BK7067","AVH.AU"],"gpt_icon":0},{"id":"2501766271","title":"Why AVITA Medical, Block, Computershare, and GQG Partners shares are falling today","url":"https://stock-news.laohu8.com/highlight/detail?id=2501766271","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501766271?lang=en_us&edition=fundamental","pubTime":"2025-01-08 09:33","pubTimestamp":1736299996,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index (ASX: XJO) has rebounded from a poor start and pushing higher on Wednesday. In afternoon trade, the benchmark index is up 0.4% to 8,317.1 points. Four ASX shares that have failed ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/08/why-avita-medical-block-computershare-and-gqg-partners-shares-are-falling-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7157","BK7033","BK7508","AVH.AU","BK7067","XJO.AU","SQ2.AU","CPU.AU","BK7503","BK7062","BK7158","GQG.AU"],"gpt_icon":0},{"id":"2501763582","title":"Avita Medical Lowers Q4, 2024 Revenue Guidance; Provides 2025 Forecast; Shares Slump 20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2501763582","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501763582?lang=en_us&edition=fundamental","pubTime":"2025-01-08 08:55","pubTimestamp":1736297748,"startTime":"0","endTime":"0","summary":"Avita Medical  lowered its commercial revenue guidance for the fourth quarter of 2024 to AU$18.4 million from the previous AU$22.3 million to AU$24.3 million, according to a Wednesday filing with the Australian bourse.The downgrade was due to a \"more pronounced\" slowdown in purchasing activity during the reported period, with deferred purchases expected to pick up in the first quarter of the year, the filing said.In addition, the regenerative medicine company decreased its 2024 commercial revenue forecast to AU$64.3 million from the previous AU$68 million to AU$70 million, per the filing.Avita Medical anticipates commercial revenue in the range of AU$100 million to AU$106 million in 2025 as it expects to achieve profitability by the fourth quarter instead of the third quarter, the filing added.Company shares slumped almost 20% in recent Wednesday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AVH.AU"],"gpt_icon":0},{"id":"2501575737","title":"Why did this ASX All Ords stock just crash 17%?","url":"https://stock-news.laohu8.com/highlight/detail?id=2501575737","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501575737?lang=en_us&edition=fundamental","pubTime":"2025-01-08 07:38","pubTimestamp":1736293126,"startTime":"0","endTime":"0","summary":"AVITA Medical Inc  shares are having a tough time on Wednesday. In morning trade, the ASX All Ords stock is down 17% to $3.62. Why is this ASX All Ords stock down 17%?This commercial-stage regenerative medicine company's shares are being sold off this morning after it revealed a softer-than-expected finish to FY 2024. According to the release, demand for its wound care management and skin restoration devices was below expectations in the fourth quarter. As a result, it now expects commercial revenue to be approximately US$18.4 million for the three months. While this represents growth of around 30% over the prior corresponding period, it is short of its fourth-quarter guidance range of US$22.3 million to US$24.3 million. As a result, its revenue in FY 2024 is also going to be short of guidance. Management expects its full year commercial revenue to be approximately US$64.3 million, reflecting growth of about 29% over FY 2023. Whereas it previously provided FY 2024 revenue guidance of U","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/08/why-did-this-asx-all-ords-stock-just-crash-17/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["AVH.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2495131916","title":"Exploring High Growth Tech Stocks in the United States December 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2495131916","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495131916?lang=en_us&edition=fundamental","pubTime":"2024-12-31 22:02","pubTimestamp":1735653771,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the United States market has dropped 1.1%, yet it has risen by an impressive 22% over the past year, with earnings forecasted to grow by 15% annually. In this context of fluctuating short-term performance and promising long-term growth, identifying high growth tech stocks requires a focus on companies with strong innovation potential and robust financial health to capitalize on future opportunities.Top 10 High Growth Tech Companies In The United States. Overview: AVITA Medical, Inc. is a regenerative medicine company that develops and commercializes innovative therapies for skin restoration in the United States and internationally, with a market cap of $354.12 million.Operations: AVITA Medical generates revenue primarily from its Recell Devices, totaling $60.04 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exploring-high-growth-tech-stocks-140251042.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4023","PGY","RCEL","AVH.AU","BK4211","BK4157","CXT","BK4161","UBCP","PGYWW"],"gpt_icon":0},{"id":"2495445687","title":"Why AVITA Medical, Life360, Newmont, and St Barbara shares are falling today","url":"https://stock-news.laohu8.com/highlight/detail?id=2495445687","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495445687?lang=en_us&edition=fundamental","pubTime":"2024-12-31 08:41","pubTimestamp":1735605689,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index(ASX: XJO) is having a disappointing finish to the year. At the time of writing, the benchmark index is down 0.7% to 8,174.7 points. Four ASX shares that are falling more than most","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/31/why-avita-medical-life360-newmont-and-st-barbara-shares-are-falling-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["AVH.AU","BK7067","NEM.AU","LIF","SBM.AU","XJO.AU","BK7016","BK7104","BK7506","360.AU","BK4023","BK7508"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":34,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AVH.AU\",params:#limit:5,,,undefined,":[{"date":"2023-08-10","symbol":"AVH.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1691625600000,"name":null,"time":"","dateTimestamp":1691589600000,"actualEps":null},{"date":"2023-05-11","symbol":"AVH.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1683763200000,"name":null,"time":"","dateTimestamp":1683727200000,"actualEps":null},{"date":"2023-02-23","symbol":"AVH.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1677106800000,"name":null,"time":"","dateTimestamp":1677070800000,"actualEps":null},{"date":"2022-11-10","symbol":"AVH.AU","type":"earning","reportTimeType":"post","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1668034800000,"name":null,"time":"Post Market","dateTimestamp":1667998800000,"actualEps":null},{"date":"2022-08-11","symbol":"AVH.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1660176000000,"name":null,"time":"","dateTimestamp":1660140000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AVH.AU\",market:\"AU\",,,undefined,":[]}}